Articles by NSF-DBA (USA) LLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by NSF-DBA (USA) LLC

NSF-DBA (USA) LLC


Articles
Are You Prepared for New Elemental Impurities Guidelines?
June 26, 2013

The pharmaceutical industry is facing great uncertainty about new elemental impurities guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). These guidelines are currently being developed and have recently reached consensus agreement and will be submitted for public consultation. Even those of us involved in the crafting of the new guidelines know significant changes are coming, but we won't know every detail of the changes until after the ICH approves and publishes the new guidelines. In line with ICH, we also have to contend with revisions to United States Pharmacopeia (USP) General Chapters and approach to elemental impurities. So what do we do until then?

Finding the Balance Between Pharmaceutical Quality Management and Manufacturing Productivity
May 29, 2013

In the pharmaceutical manufacturing industry, our primary concern must always be the quality and safety of our processes and the products we produce. If we don't focus appropriately on developing robust quality management systems, we risk consumer safety and put our companies at risk of regulatory action. Learn more about how to achieve this in this white paper from the experts at NSF-DBA LLC.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here